APA (7th ed.) Citation

FP, M. R., G, X., GF, K., J, N., OI, O., R, M., . . . J, B. (2023). Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. BioRxiv : the preprint server for biology. https://doi.org/10.1101/2023.06.22.544406

Chicago Style (17th ed.) Citation

FP, Madorsky Rowdo, et al. "Patient-derived Tumor Organoids with P53 Mutations, and Not Wild-type P53, Are Sensitive to Synergistic Combination PARP Inhibitor Treatment." BioRxiv : The Preprint Server for Biology 2023. https://doi.org/10.1101/2023.06.22.544406.

MLA (9th ed.) Citation

FP, Madorsky Rowdo, et al. "Patient-derived Tumor Organoids with P53 Mutations, and Not Wild-type P53, Are Sensitive to Synergistic Combination PARP Inhibitor Treatment." BioRxiv : The Preprint Server for Biology, 2023, https://doi.org/10.1101/2023.06.22.544406.